FDA Preemption: Agency’s Proposed Labeling Rule Riles Plaintiffs’ Bar
Executive Summary
FDA's proposal to restrict when companies can revise product labeling without first getting agency approval drew a sharp reaction from lawyers involved in product liability litigation
You may also be interested in...
FDA’s Labeling Rule Should Be Tweaked, Firms Say; Dems Want It Squashed
FDA appears to have a relatively smooth task ahead of itself as it works to finalize its proposed rule delineating when firms can change product labels without prior agency approval since the comments supporting the proposal contain few suggested changes
FDA’s Labeling Rule Should Be Tweaked, Firms Say; Dems Want It Squashed
FDA appears to have a relatively smooth task ahead of itself as it works to finalize its proposed rule delineating when firms can change product labels without prior agency approval since the comments supporting the proposal contain few suggested changes
FDA Preemption Deadlocks Supreme Court; Congress Pushes To Resolve Issue
Citing a crisis within FDA, members of Congress are demanding that the agency withdraw its proposed rule to limit when drug and device manufacturers can revise their product labeling without prior FDA approval